The HeMoVal study protocol: a prospective international multicenter cohort study to validate cerebrospinal fluid hemoglobin as a monitoring biomarker for aneurysmal subarachnoid hemorrhage related secondary brain injury.

Publication

The HeMoVal study protocol: a prospective international multicenter cohort study to validate cerebrospinal fluid hemoglobin as a monitoring biomarker for aneurysmal subarachnoid hemorrhage related secondary brain injury.

Journal Paper/Review - Jul 18, 2022

Akeret Kevin, Buzzi Raphael, Saxenhofer Moritz, Bieri Kathrin, Chiavi Deborah, Thomson Bart R, Grüttner-Durmaz Manuela, Schwendinger Nina, Humar Rok, Regli Luca, van Doormaal Tristan P C, Held Ulrike, Keller Emanuela, Hugelshofer Michael, Schaer Dominik J, Hostettler Isabel C

Citation

Akeret K, Buzzi R, Saxenhofer M, Bieri K, Chiavi D, Thomson B, Grüttner-Durmaz M, Schwendinger N, Humar R, Regli L, van Doormaal T, Held U, Keller E, Hugelshofer M, Schaer D, Hostettler I. The HeMoVal study protocol: a prospective international multicenter cohort study to validate cerebrospinal fluid hemoglobin as a monitoring biomarker for aneurysmal subarachnoid hemorrhage related secondary brain injury. BMC Neurol 2022; 22:267.

Type

Journal Paper/Review (English)

Journal

BMC Neurol 2022; 22

Publication Date

Jul 18, 2022

Issn Electronic

1471-2377

Pages

267

Brief description/objective

Preclinical studies provided a strong rationale for a pathophysiological link between cell-free hemoglobin in the cerebrospinal fluid (CSF-Hb) and secondary brain injury after subarachnoid hemorrhage (SAH-SBI). In a single-center prospective observational clinical study, external ventricular drain (EVD) based CSF-Hb proved to be a promising biomarker to monitor for SAH-SBI. The primary objective of the HeMoVal study is to prospectively validate the association between EVD based CSF-Hb and SAH-SBI during the first 14 days post-SAH. Secondary objectives include the assessment of the discrimination ability of EVD based CSF-Hb for SAH-SBI and the definition of a clinically relevant range of EVD based CSF-Hb toxicity. In addition, lumbar drain (LD) based CSF-Hb will be assessed for its association with and discrimination ability for SAH-SBI.